People searching for a GHK-Cu dose usually want a number: a percentage for a serum, or milligrams for an injection. No approved product carries a label for this copper peptide. What exists is a short list of studies, each with its own concentration, and very few measured a clinical outcome against placebo.
This page lists those amounts and says what each study was testing. It does not suggest a dose. The side-effect record is covered in GHK-Cu side effects.
Why there is no standard dose
A dose normally comes from a label, and a label comes from trials that compared amounts. GHK-Cu has never been through that process for any use.
A 2026 systematic review of GHK-Cu in aesthetic medicine found 20 studies, 18 of them in cells or animals [5]. Its authors call for future trials with standardized formulations, dosing regimens and delivery methods. In other words, no agreed dosing regimen exists yet.
A 2025 review of GHK as a wrinkle ingredient reached a similar point by another route [6]. It found published information on skin permeability and effectiveness insufficient, despite wide use in commercial products.
What the human and skin studies used
| Study | Who or what | Amount used | Result |
|---|---|---|---|
| Venous ulcer trial, 1992 | 86 evaluable patients, three arms | 0.4% cream | No better than placebo |
| Laser resurfacing trial, 2006 | 13 patients completed | Not stated in the abstract | No objective difference; higher satisfaction |
| Skin penetration, 2010 | Human skin samples in the lab | 0.68% aqueous solution | Copper crossed dermatomed skin over 48 hours |
| Microneedle study, 2015 | Human skin in the lab | Not a dose study | Almost none crossed intact skin |
The 0.4% cream on leg ulcers
A placebo-controlled trial published in 1992 used a tripeptide copper complex as a 0.4% cream [1]. It enrolled patients with venous stasis ulcers, and 86 evaluable patients completed it.
The trial had three arms: the copper peptide cream, a 1% silver sulfadiazine cream and an inert placebo. Silver sulfadiazine reduced ulcer size compared with the other two. The copper peptide cream showed no difference from placebo.
That result is for chronic wounds on the legs, not for facial skin or hair. It remains the clearest published test of a stated GHK-Cu strength against placebo.
The laser resurfacing trial
A 2006 trial gave patients skin care with or without GHK-Cu after carbon dioxide laser resurfacing around the mouth [2]. Thirteen patients completed it.
Its abstract describes the treatment as skin care products and does not give a concentration. Blinded evaluators found no difference in redness, wrinkles or skin quality. Patients using GHK-Cu rated their skin quality higher on a questionnaire (P = .04).
What reaches the skin in the lab
A concentration on a bottle is not the amount that gets into skin. Two lab studies on human skin samples measured that gap.
A 2010 study applied a 0.68% aqueous solution of copper as the tripeptide to human skin in diffusion cells [3]. Over 48 hours, 136.2 micrograms of copper per square centimeter crossed dermatomed skin, and 82 micrograms stayed in it. The study measured copper, not the intact peptide.
A 2015 study measured the peptide itself [4]. Through human skin pretreated with microneedles, 134 nanomoles of peptide crossed in 9 hours. Through intact human skin, almost no peptide or copper crossed.
Both results come from skin samples, not people. They suggest that the same percentage can deliver very different amounts depending on whether the skin barrier is broken. Why that matters for choosing a route is set out in GHK-Cu topical vs injected.
Injected GHK-Cu: no established dose
No published study has given people GHK-Cu on its own by injection. No human injected dose has been established, and any figure sold with an injectable vial does not come from a trial.
The nearest study injected a hair formulation into the scalps of 1,000 patients, once every 3 weeks for eight sessions [7]. That formulation combined a copper tripeptide with five other active ingredients, four growth factors and thymosin beta-4. The study was open-label with no control group, and its abstract gives no amount of the copper peptide. It cannot show a dose of GHK-Cu.
What this means
The honest answer to the dosage question is that no dose of GHK-Cu has been shown to work in a controlled human trial. The one tested strength, 0.4% on leg ulcers, matched placebo.
For a product on skin, the first thing to ask is its concentration, and not every seller prints it. The CoreAge Rx review notes that its repair cream lists a copper peptide with no strength given.
What topical GHK-Cu has shown on the face and scalp is covered in peptides for skin and peptides for hair growth. For other options with human data, start at the recovery goal page.